AbbVie's announcement comes just days after President Trump announced an exemption on pharma tariffs for companies that have broken ground on a US-based manufacturing site. The press release also affirms that this move is part of AbbVie’s commitment to expand its US-based manufacturing presence. At the time of the announcement, AbbVie stated that it planned on beginning construction in fall of 2025. Late last week, President Trump announced plans to implement 100% tariffs on branded and patented drugs imported to the US starting October 2025. However, he provided an exception for companies that had already begun construction or broken ground on US-based manufacturing facilities.